We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

By LabMedica International staff writers
Posted on 25 Apr 2024

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB. More...

The World Health Organization estimated over 10 million new cases and 1.3 million deaths from active TB worldwide in 2022. Additionally, antimicrobial resistance (AMR) poses a growing challenge in TB treatment, with drug-resistant strains occurring in about 4% of all TB cases. Now, a next-generation sequencing (NGS) panel enables culture-free whole genome sequencing directly from complex samples could significantly accelerate TB outbreak tracking and enhance the detection and management of AMR—both crucial for TB surveillance and control.

QIAGEN (Venlo, the Netherlands) has launched the QIAseq xHYB Mycobacterium tuberculosis Panel for research use, furthering its commitment to global TB management and control. This includes the company’s leading diagnostics test, QuantiFERON-TB Gold Plus. The new panel facilitates culture-free whole genome sequencing (WGS) directly from clinical samples such as sputum or cerebrospinal fluid. This breakthrough reduces the time to obtain results and enables real-time epidemiology for TB outbreaks, meeting a critical need in TB surveillance and control. The QIAseq xHYB Mycobacterium tuberculosis Panel marks a significant advancement in conducting bacterial WGS from complex host samples, employing NGS. Designed to target the seven major TB lineages, it encompasses the full spectrum of bacterial diversity. By eliminating the need for the traditional 4-to-6-week bacterial culture, the panel speeds up the process of obtaining results

Additionally, the QIAseq xHYB Mycobacterium tuberculosis Panel is crucial for the detection and management of AMR. It covers all genes related to AMR, enabling the identification of resistant TB strains, including multidrug-resistant tuberculosis (MDR-TB) caused by bacteria resistant to the most effective first-line TB drugs. This surveillance capability is vital for tracking the emergence and spread of drug resistance, providing essential data to update treatment protocols and stimulating research and development for new TB treatments and diagnostic tools, ultimately enhancing patient outcomes.

“The introduction of the QIAseq xHYB Mycobacterium tuberculosis Panel reflects our ongoing commitment to address global health challenges like TB and antimicrobial resistance,” said Nitin Sood, Vice President, Head of the Life Sciences Business Area at QIAGEN. “This innovative panel not only streamlines the workflow for healthcare professionals and researchers but also enables the real-time tracking of TB outbreaks, a crucial aspect in combating the spread of this devastating disease and managing the growing threat of drug-resistant TB.”


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.